What is Shanghai Pharmaceuticals Holding Co Median PS Value?
Shanghai Pharmaceuticals Holding CoSHPMY -3.42%79 Median PS Value is $10.75 as of Jun. 30, 2026, which is 1373% above its 10-year median of 0.73. GuruFocus rates SHPMY with a GF Score™ of 79/100 and a GF Value™ of $9.50 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 70 Medical Distribution companies, Shanghai Pharmaceuticals Holding Co ranks better than 57.14% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
SHPMY'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.53 Med: 0.73 Max: 1.24
Current: 0.68
During the past 13 years, the highest Price to Median PS Value of Shanghai Pharmaceuticals Holding Co was 1.24. The lowest was 0.53. And the median was 0.73.
SHPMY's Price-to-Median-PS-Value is ranked better than 57.14% of 70
companies
in the Medical Distribution industry
Industry Median: 0.805
vs SHPMY: 0.68
Shanghai Pharmaceuticals Holding Co (OTCPK:SHPMY) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Shanghai Pharmaceuticals Holding Co's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
7.3398
/
10.75
=
0.68
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Pharmaceuticals Holding Co Median PS Value Related Terms
Shanghai Pharmaceuticals Holding Co Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Pharmaceuticals Holding Co Median PS Value Chart
SHPMY vs MCK, CAH, COR: Median PS Value Comparison
For the Medical Distribution subindustry, Shanghai Pharmaceuticals Holding Co's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Pharmaceuticals Holding Co Price-to-Median-PS-Value vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Shanghai Pharmaceuticals Holding Co's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Shanghai Pharmaceuticals Holding Co's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.1961.
Shanghai Pharmaceuticals Holding Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $54.821.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Pharmaceuticals Holding Co (SHPMY) has a Median PS Value of $10.75 as of Jun. 30, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Shanghai Pharmaceuticals Holding Co and its competitors. This is 1373% above median its historical median of 0.73. Over the past decade, Shanghai Pharmaceuticals Holding Co's Median PS Value has ranged from 0.53 to 1.24. According to the industry distribution chart, Shanghai Pharmaceuticals Holding Co ranks #30 out of 70 companies in the Medical Distribution industry, placing it in the top 42.9%.
Is Shanghai Pharmaceuticals Holding Co's Median PS Value too high?
Shanghai Pharmaceuticals Holding Co's current Median PS Value of $10.75 is 1373% above median its 10-year median of 0.73. Over the past 10 years, this metric has ranged from a low of 0.53 to a high of 1.24. The Medical Distribution industry median Median PS Value is 0.81. Shanghai Pharmaceuticals Holding Co's value of $10.75 is 1235.4% above this industry median. Based on the distribution chart, Shanghai Pharmaceuticals Holding Co ranks #30 out of 70 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Shanghai Pharmaceuticals Holding Co has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Pharmaceuticals Holding Co's Median PS Value compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Shanghai Pharmaceuticals Holding Co ranks #30 out of 70 companies for Median PS Value. This puts Shanghai Pharmaceuticals Holding Co in the upper half of its industry. The industry median Median PS Value is 0.81. Shanghai Pharmaceuticals Holding Co's value of $10.75 is 1235.4% above this benchmark. Historically, Shanghai Pharmaceuticals Holding Co's own Median PS Value has ranged from 0.53 to 1.24 over the past decade. While the company's 10-year median is 0.73 vs. the industry median of 0.81, Shanghai Pharmaceuticals Holding Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Distribution company?
The median Median PS Value among Medical Distribution companies is 0.81, based on 70 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Pharmaceuticals Holding Co's current Median PS Value of $10.75 is 1235.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Shanghai Pharmaceuticals Holding Co and its competitors. For the Medical Distribution industry, the median Median PS Value is 0.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Pharmaceuticals Holding Co's current Median PS Value is $10.75, which is 1373% above median its own 10-year median of 0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Pharmaceuticals Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Pharmaceuticals Holding Co (SHPMY) is currently considered Modestly Undervalued. The stock's GF Value™ is $9.50, compared to a current price of $7.34 — trading 22.7% below its estimated fair value. The current Median PS Value is $10.75, which is 1373% above median its 10-year median of 0.73 and 1235.4% above the Medical Distribution industry median of 0.81. Shanghai Pharmaceuticals Holding Co's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Shanghai Pharmaceuticals Holding Co (SHPMY), the current Median PS Value is $10.75 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Pharmaceuticals Holding Co (SHPMY) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Pharmaceuticals Holding Co stock appears to be undervalued.
The current stock price of $7.34 is trading 22.7% below its estimated GF Value™ of $9.50.
GuruFocus considers Shanghai Pharmaceuticals Holding Co to be Modestly Undervalued.
Key valuation signals for SHPMY:
Median PS Value: $10.75 (1373% above median its 10-year median of 0.73)
GF Value™: $9.50 vs. price of $7.34 (22.7% below fair value)
Industry Position: 1235.4% above the Medical Distribution median (#30 of 70)
No single metric tells the full story. See the SHPMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Pharmaceuticals Holding Co Business Description
Shanghai Pharmaceuticals Holding Co Ltd is engaged in the pharmaceutical drug development and distribution business. The Group's reportable segments are: Production, Distribution, Retail, and Other. The majority of its revenue comes from the Distribution segment, which is mainly engaged in distribution, warehousing, and other value-added pharmaceutical supply chain solutions and related services for pharmaceutical manufacturers and dispensers. The Retail segment operates a network of retail pharmacy stores, and the Production segment is mainly engaged in research and development, production, and sales of a broad range of pharmaceutical and healthcare products. Geographically, the Group mainly operates in the People's Republic of China (PRC).
79GF Score
Get the complete analysis for SHPMY
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHPMY has been successfully added to your 
